{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ParadigMM-1B","nct_id":"NCT03287908","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=paradigmm-1b-nct03287908. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"AMG 701","type":"EXPERIMENTAL"},{"description":null,"label":"AMG 701 + Pomalidomide","type":"EXPERIMENTAL"},{"description":null,"label":"AMG 701 + Pomalidomide + Dexamethasone","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-06-30","type":"ACTUAL"},"conditions":["Relapsed/Refractory Multiple Myeloma"],"enrollment":{"count":174,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AMG 701","otherNames":[],"type":"DRUG"},{"name":"Pomalidomide","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"}],"last_update":"2025-10-08","lead_sponsor":"Amgen","official_title":"A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2023-06-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of subjects with dose-limiting toxicities (DLTs)","timeFrame":"28 days"},{"measure":"Number of subjects with treatment emergent adverse events (TEAEs)","timeFrame":"60 months"},{"measure":"Number of subjects with treatment-related adverse events","timeFrame":"60 months"},{"measure":"Number of subjects with disease-related adverse events","timeFrame":"60 months"},{"measure":"Number of subjects with clinically-significant changes in vital signs","timeFrame":"48 months"},{"measure":"Number of subjects with clinically-significant changes in physical examination measurements","timeFrame":"48 months"},{"measure":"Number of subjects with clinically-significant changes in electrocardiogram (ECG) measurements","timeFrame":"48 months"},{"measure":"Number of subjects with clinically-significant changes in clinical laboratory tests","timeFrame":"48 months"}],"references":[{"citation":"Lee HC, Plattel WJ, Harrison SJ, Sborov DW, Lentzsch S, Spencer A, Niesvizky R, Trudel S, Mollee P, Vij R, Minnema MC, Rasche L, Upreti VV, Zhou D, Xia Q, Talpes M, Eggert T, Kapoor P, Ailawadhi S. A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma. Blood. 2026 Jul 9;148(2):199-212. doi: 10.1182/blood.2025032044.","pmid":"41950113","type":"DERIVED"},{"citation":"Cho SF, Lin L, Xing L, Li Y, Wen K, Yu T, Hsieh PA, Munshi N, Wahl J, Matthes K, Friedrich M, Arvedson T, Anderson KC, Tai YT. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 Sep 8;4(17):4195-4207. doi: 10.1182/bloodadvances.2020002524.","pmid":"32898244","type":"DERIVED"}],"start_date":{"date":"2017-11-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT03287908"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/paradigmm-1b-nct03287908"}